Invest in the Future of Cancer Therapy
Pre-IPO Investment Opportunity
At NOK Therapeutics, we are pioneering a breakthrough approach to cancer treatment with autologous Natural Killer (NK) cell therapies. Our innovative science eliminates the need for lymphodepletion, making advanced cancer treatment safer, more accessible, and more effective.
With a focus on harnessing a patient’s own immune system, our therapies enable deeper, longer remissions and expand access to cutting-edge cancer care.
Now, you have the opportunity to invest in NOK Therapeutics before we go public. Be part of the next generation of oncology innovations.
4 Reasons Why You Should Invest in NOK Tx Now
Lead Investors In NOK Therapeutics
NOK Therapeutics is proud to have the support of MedTek and J. Bradley Hilton with the Hilton Finance Office who have both made strategic investments in the company.
“We believe NOK’s innovative approach to cancer therapy represents a paradigm shift in oncology. Their autologous NK cell technology has the potential to transform patient care and redefine how cancer is treated.”
“As an investor in the medical technology industry, I recognize the value of breakthrough innovations that push the boundaries of science and patient care. NOK Therapeutics is leading the way in autologous NK cell therapy, offering a revolutionary approach to cancer treatment without the need for lymphodepletion. After extensive due diligence, I was highly impressed by NOK’s leadership team, their cutting-edge research, and their commitment to transforming oncology care. Their focus on delivering effective, personalized immunotherapy aligns with the future of medicine, making this an investment with both significant impact and potential returns. NOK Therapeutics is not just another biotech company—it’s a game-changer in the fight against cancer. I’m proud to be part of their journey and look forward to seeing their therapies change lives worldwide.”
Investment Structure & Offering Details
- Offering Type: Regulation A+ Tier II
- Investment Minimum: $5,000
- Share Price: $2.00 per share
- Offering Size: $10,000,000
- Investor Eligibility: Open to both accredited and non-accredited investors
- Use of Funds: Clinical trials, research & development, regulatory approvals, and market expansion
What People Are Saying About NOK
Frequently Asked Questions (FAQ)
What is NOK Therapeutics
NOK Therapeutics is a pioneering biotech company developing autologous Natural Killer (NK) cell therapies for cancer treatment without the need for lymphodepletion.
How is NOK's therapy different from other cell therapies?
Unlike traditional NK cell therapies, NOK’s approach eliminates the need for high-dose chemotherapy (lymphodepletion), making it safer and more accessible for more patients.
Who can invest in NOK Therapeutics?
Our Pre-IPO investment opportunity is open to accredited and non-accredited investors under the Regulation A+ offering.
What are the risks of investing in NOK Therapeutics?
As with any early-stage biotech investment, risks include regulatory approvals, market fluctuations, and clinical trial outcomes. We encourage investors to conduct their due diligence.
How do I invest?
Click the ‘Get Started’ button below to review our investment documents and complete your investment process securely.
Be Part of the Future of Cancer Therapy
Join Our Mission – Invest Today
The future of cancer treatment is here, and you have the chance to be part of it. NOK Therapeutics is revolutionizing oncology with cutting-edge NK cell therapy that eliminates the need for harsh treatments like lymphodepletion. With a massive market opportunity, a world-class leadership team, and the support of visionary investors, NOK is positioned for success.
Be an early investor before we go public! Support life-changing cancer therapies that save lives. Secure your position in the future of biotech innovation.
Click the ‘Get Started’ button now to receive exclusive investment details and secure your stake in NOK Therapeutics today!
Legal Disclaimers
Forward-Looking Statements: This website and its materials may contain forward-looking statements regarding future events, projections, and business strategies. These statements are subject to significant risks and uncertainties and should not be relied upon as guarantees of future performance.
Investment Risk: Investing in early-stage biotech companies involves risk, including the potential loss of principal. There is no guarantee of an IPO, liquidity event, or return on investment. Please consult with a financial advisor before making any investment decisions.
SEC Qualification: This Regulation A+ offering is made pursuant to an offering statement that has been qualified by the U.S. Securities and Exchange Commission (SEC). However, the SEC has not approved or endorsed the merits of this offering. Potential investors should review all offering materials carefully before investing.
No Offer or Solicitation: This webpage does not constitute an offer to sell, or a solicitation of an offer to buy, any securities. The offering is made solely through the official offering circular available at Noktx.com